1. Extranodal NK/T-Cell Lymphoma, Nasal Type
    Yexiong Li, 2017, Radiation Therapy in Hematologic Malignancies CrossRef
  2. Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis


    Jin Li et al, 2020, Therapeutics and Clinical Risk Management CrossRef
  3. Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder
    Tracy T. Batchelor et al, 2016, American Society of Clinical Oncology Educational Book CrossRef
  4. Defining the toxicity of current regimens for extranodal NK/T cell lymphoma: a systematic review and metaproportion
    Vadim S. Pokrovsky et al, 2019, Expert Review of Anticancer Therapy CrossRef
  5. Sequential DICE combined withl-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma
    Li-Hua Dong et al, 2016, Leukemia & Lymphoma CrossRef
  6. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study
    Yong Yang et al, 2015, Blood CrossRef
  7. Peripheral T cell lymphoma coexisting with Castleman's disease
    Shuyan Liu et al, 2020, Medicine CrossRef
  8. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
    Jing-hua Wang et al, 2016, Oncotarget CrossRef
  9. Efficacy and tolerance of GELOXD/P‐GEMOXD in newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma: A multicenter retrospective study
    Ji‐Wei Li et al, 2018, European Journal of Haematology CrossRef
  10. First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG
    Shu-Nan Qi et al, 2020, Blood Advances CrossRef